Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.68
EPS est.
$-0.72
EPS surprise
+6.08%
1-day move
+1.27%
Denali Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising by 1.27%. However, there was no revenue reported, and no guidance was provided, leaving investors with limited insights into future performance. The slight beat on EPS may indicate some operational efficiency, but the lack of revenue data raises questions about overall growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | +6.08% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
Denali Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. With a market cap of $4 billion, its work is crucial as the demand for effective treatments in this area continues to grow amidst an aging population.
Last quarter
In Q1-2026, Denali reported an EPS of $-0.69, slightly beating expectations. However, the stock declined by 3.43% the following day, indicating market disappointment despite the positive surprise.
EPS beat streak
5Q
EPS beat rate
75%
Avg EPS surprise
+3.12%
Avg 1-day reaction
-2.11%
Investors are cautiously optimistic about Denali's upcoming earnings, especially given its history of beating EPS estimates. However, the lack of revenue guidance adds uncertainty.
Bull case
If Denali continues its trend of beating EPS estimates, it could signal strong underlying business momentum and investor confidence.
Bear case
On the other hand, if the company fails to provide clarity on revenue or shows continued losses, it could lead to further stock declines.
Key metrics to watch
EPS (Earnings Per Share)
$-0.73EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/AWhile specific revenue estimates are not available, any growth in revenue would signal progress in Denali's drug development efforts.
The print will turn on these.
Q1
What will be the EPS figure for Q2-2026?
Given the company's history of EPS surprises, this number will be critical in shaping investor sentiment.
Q2
Will there be any updates on revenue or pipeline progress?
Clarity on revenue and drug development progress is essential for understanding the company's growth trajectory.
Est. EPS
$6.10
Est. Rev
$5.0B
Impl. Move
±5.3%
Why consensus could be wrong
The Street may be underestimating Denali's ability to control costs and improve its EPS despite ongoing losses.
Supporting evidence
Denali has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.
The options market is pricing in a significant move, suggesting that traders expect a more favorable outcome than consensus.
Recent trends in biotech suggest a potential rebound in investor sentiment towards companies with promising pipelines.
Key risk
If Denali's EPS comes in better than expected, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The market is debating whether Denali can maintain its positive EPS surprise trend amidst ongoing financial challenges.
Bull confirmed if
An EPS of $-0.65 or better would confirm the bull case, indicating improved financial performance.
Bear confirmed if
An EPS worse than $-0.75 would confirm the bear case, raising concerns about ongoing losses.
What the market is pricing for the move.
Implied Move
±27.57%
Historical Avg
±4.1%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±27.6% while DNLI has averaged ±4.1% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
48.7%
Smart-money positioning from the most recent 13F filings.
Institutional
101.29%
of float
Insider
4.61%
of float
Holders
411
institutions
Top Holders· as of Jun 2026
T. Rowe Price Investment Management, Inc.
16,178,963 sh · $310.0M
10.12%
89.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Denali beats expectations, history suggests the stock could rise by around 2.8%, confirming positive momentum.
In line / cautious
If results are in line with expectations, the stock may see muted reactions as investors await further clarity.
Miss
If Denali misses estimates, history suggests a decline of about 2.9%, which could heighten concerns about its financial health.
The lines on the call that would change the story.
Blackrock Inc.
14,026,413 sh · $268.7M
8.77%
7.6%
BAILLIE GIFFORD & CO
11,960,230 sh · $229.2M
7.48%
-0.9%
State Street Corporation
7,049,304 sh · $135.1M
4.41%
12.4%
Temasek Holdings (Private) Ltd
7,012,974 sh · $134.4M
4.39%
Flat
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.